Two patients. Same hospital. Same diagnosis: lung cancer. Both receive the same chemotherapy. One responds well. The other doesn’t. For decades, cancer treatment followed a simple rule. Identify where ...

FDA authorized the first generic baloxavir marboxil, a cap-dependent endonuclease inhibitor, expanding single-dose influenza antiviral access and introducing a new competitor to the branded product ...

Walk down the spice aisle of any grocery store, and you'll find a familiar scene: the name brand jars up front, clean and bold, carrying a price that's two or three times higher than the store brand ...

For many financial institutions, the first phase of enterprise AI adoption has followed an all too familiar script. Connect a large language model to internal data, layer on retrieval tools, and ...

Nandan Kulkarni, Director at Bernstein, has a message for investors still valuing Indian pharmaceutical companies purely on their US generics pipeline: that playbook is becoming obsolete. In a ...

A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline. Josua Lottering ...

The modern morning routine typically begins with a familiar, mechanical ritual that involves stumbling into the kitchen to ...

A generic semaglutide injection to promote weight loss is now approved in Canada, Health Canada says. The regulator said the product submission, called Svemia, was filed by Canadian-based Apotex and ...

Brew a pesticide-free cup of joe with the best organic coffee. Our coffee expert tested over a dozen bags to find the perfect ...

Corin Cesaric-Epple is an Editor at CNET covering home and kitchen tech and meal kits, and reporting regularly on artificial intelligence. She earned her bachelor's degree in journalism from the ...

LEHI, Utah, June 25, 2026 /PRNewswire/ -- CivicaScript's transparent, nonprofit business model saved patients and payer members more than $16 million in 2025 after they switched to its low-cost ...